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ABSTRACT. Calcitonin gene-related peptide (CGRP) is a neuropeptide that is involved 
in the transmission of pain. Drugs targeting CGRP or a CGRP receptor are efficacious in 
the treatment of migraine. The canonical CGRP receptor is a complex of a G protein-
coupled receptor, the calcitonin-like receptor (CLR) with an accessory protein, receptor 
activity-modifying protein 1 (RAMP1). A second receptor, the AMY1 receptor, a complex 
of the calcitonin receptor with RAMP1, is a dual high affinity receptor for CGRP and 
amylin. Receptor regulatory processes, such as internalization, are crucial for controlling 
peptide and drug responsiveness. Given the importance of CGRP receptor activity in 
migraine we compared the internalization profiles of both receptors for CGRP using novel 
fluorescent probes and a combination of live cell imaging, fixed cell imaging and ELISA. 
This revealed stark differences in the regulation of each receptor with the AMY1 receptor 
unexpectedly showing little internalization. 
 
Migraine is a debilitating illness, which affects approximately 15% of the population1.  
Drugs targeting the calcitonin gene-related peptide (CGRP) system have emerged as 
breakthrough therapies in the treatment of migraine2. 
 
CGRP is a 37 amino acid neuropeptide that is widely expressed in the nervous system, 
and has an important role in the transmission of pain in migraine3. Drugs that block CGRP 
signaling do so either by blocking the CGRP peptide or a CGRP receptor. These drugs 
have consistently demonstrated efficacy in clinical trials in the treatment of migraine. 
Currently one monoclonal antibody targeting a CGRP receptor (erenumab) has received 
clinical approval in addition to three monoclonal antibody drugs targeting the CGRP 
peptide (galcanezumab, eptinezumab and fremanezumab). Two of these are also 
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clinically approved2. Furthermore, several small molecule drugs that have been designed 
to target the CGRP receptor are also under development or clinically approved (gepants), 
including rimegepant, ubrogepant and atogepant4. 
 
The canonical receptor for CGRP is a heterodimer of a G protein-coupled receptor 
(GPCR), the calcitonin-like receptor (CLR) with the accessory protein receptor activity-
modifying protein 1 (RAMP1) (Figure 1A)5. Activation of the CGRP receptor results in 
accumulation of cAMP6. Following agonist stimulation, the CGRP receptor undergoes 
internalization in a β-arrestin and clathrin-dependent manner; chronic stimulation of the 
CGRP receptor results in trafficking to lysosomes, followed by degradation, whereas 
transient stimulation results in recycling of the receptor to the cell surface7, 8. The 
internalization of GPCRs was originally thought to result in the termination of signaling. 
Several GPCRs including the CGRP receptor have now been observed to signal from 
endosomes9, 10. In the case of the CGRP receptor, endosomal signaling is reportedly 
important for CGRP signaling in pain transmitting neurons10. Thus, where a receptor 
resides in a cell potentially represents distinct opportunities or challenges for drug 
targeting. 
 
In addition to the canonical CGRP receptor, there is a second CGRP responsive receptor, 
the AMY1 receptor, which comprises the calcitonin receptor (CTR) with RAMP15 (Figure 
1A). Previous work has found that the AMY1 receptor is also expressed within trigeminal 
neurons, suggesting it may also be a target for migraine11. However this receptor is also 
a high affinity receptor for amylin, a peptide that is closely related to CGRP. An amylin 
analogue, pramlintide is approved for use in insulin-requiring diabetes12. It is not known 
what contribution the AMY1 receptor makes, if any, to amylin physiology. In contrast to 
the CGRP receptor, the internalization properties of the AMY1 receptor have not been 
investigated, although the CTR is reported to undergo internalization8.   
 
To determine how the AMY1 receptor may be regulated and to compare this to CGRP 
receptor regulation, we developed new fluorescently labeled peptide probes. These have 
allowed us to investigate the internalization properties of both the AMY1 and CGRP 
receptors. We observe marked differences in internalization, with the AMY1 receptor 




Figure 1. Receptors, fluorescently labelled agonists and their pharmacology. (A) Overview of CGRP and 
AMY1 receptors and their pharmacology. In this figure, > refers to a difference of ~100-1000 fold. (B) Peptide 
sequences, illustrating the position of the Cy5 fluorescent label in CGRP and pramlintide. (C) cAMP 
production in response to [Cy53]-hαCGRP and [Cy521]-pramlintide at the CGRP and AMY1 receptors, 
compared to controls in Cos-7 cells. In panel (C), the data points are mean ± s.e.m., combined from five 
independent experiments performed in triplicate. Statistical analysis is reported in Table S1.  
 
Results and Discussion  
We developed a series of fluorescent peptides as tools to investigate the internalization 
properties of the CGRP and AMY1 receptors (Figure 1B, Supporting Information). 
hαCGRP labeled at position 3 with a Cy5 fluorophore (Figure 1B), [Cy53]-hαCGRP, was 
equipotent to unlabeled hαCGRP at stimulating cAMP production at both the CGRP and 
AMY1 receptors (Figure 1C, Figure S1,Table S1, Figure S2) consistent with previous 
results demonstrating that labeling hαCGRP at this position does not affect potency13. 
The peptide also had equivalent activity between the CGRP and AMY1 receptors, 
consistent with the pharmacology of CGRP itself (Table SB1)5. This probe was further 
tested at additional signaling pathways, with similar results (Table S2, Figure S3). We 
also prepared [Cy521]-hαCGRP, which had a similar pharmacological profile to [Cy53]-
hαCGRP, and hαCGRP at the CGRP and AMY1 receptors (Table S1). The amylin 
analogue pramlintide was labelled at position 21 with Cy5, resulting in the ligand [Cy521]-
pramlintide. Consistent with the pharmacology of amylin and pramlintide, this peptide was 
~100-fold weaker at the CGRP receptor compared to the AMY1 receptor, at which it was 
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a potent agonist that was no different to unlabelled pramlintide (Figure 1C, Table S1). 
We additionally profiled the activity of all fluorescent peptides at CTR, other amylin 
receptors (AMY2, AMY3) and the adrenomedullin receptors (AM1, AM2), to gain a fuller 
understanding of effects across the CLR or CTR/RAMP complexes (Figure S1, Table 
S1, Figure S2). There was a trend towards increased activity upon peptide labelling. On 
the basis of these data, between the two CGRP peptides we selected [Cy53]-hαCGRP for 
the majority of our experiments because its activity was overall more similar to hαCGRP 
than was [Cy521]-hαCGRP. 
 
 
Figure 2. The CGRP receptor internalizes robustly in response to hαCGRP. (A) Localization of [Cy53]-
hαCGRP in CGRP receptor transfected HEK293S cells, which was quantified at (B) varying time-points 
and (C) peptide concentrations. [Cy53]-hαCGRP co-localization with (D) EEA-1 or (E) Myc-RAMP1 and HA-
CLR in CGRP receptor transfected HEK293S cells. (F) Changes in cell surface expression of CGRP 
receptor components by ELISA in HEK293S cells. In panels (A), (D) and (E), the images are representative 
of five (A, E) or four (D) independent experiments performed in duplicate. White arrows mark examples of 
spots. Scale bars = 20 µM. Other data are mean ± s.e.m., combined from five to ten (B) or five (C, F) 
independent experiments performed in duplicate or triplicate. In (B), * p < 0.05 compared to vector 
transfected cells by repeated measures two-way ANOVA with a post hoc Bonferroni’s test. In (C), * p <0.05 
compared to vector transfected cells by Student’s unpaired t-test at 100 nM [Cy53]-hαCGRP. In (F), * p < 
0.05 (myc) or † p < 0.05 (HA) compared to vehicle treated cells (data not shown) at each time point by 
repeated measures two-way ANOVA with a post hoc Bonferroni’s test. In (A), (B), (D), (E) 10 nM [Cy53]-
hαCGRP was used. 
 
We used [Cy53]-hαCGRP to investigate the internalization properties of the CGRP and 
AMY1 receptors using live cell imaging. Transiently transfected HEK293S cells were 
incubated with 100 nM [Cy53]-hαCGRP and imaged. After approximately 15 minutes, 
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[Cy53]-hαCGRP became visible as puncta within the cytoplasm of CGRP receptor 
transfected cells (Movie 1). This is similar to our prior observations with a TAMRA labelled 
CGRP peptide at this receptor13. In contrast, in cells transfected with the AMY1 receptor, 
[Cy53]-hαCGRP staining was clearly visible on the plasma membrane, but very little 
fluorescence was observed within the cytoplasm in time courses up to one hour (Movie 
2). Movie 3 shows vector transfected cells incubated with peptide for comparison. In 
addition, we tested [Cy521]-hαCGRP in live cell imaging, with similar results at both 
receptors (Figure S4). Imaging of fixed cells was used to quantify the internalization of 
[Cy53]-hαCGRP at each receptor, by measuring the number of spots within the cytoplasm 
with the plasma membrane excluded (Figure S5-6). For these experiments, transfected 
HEK293S cells were incubated with [Cy53]-hαCGRP at different time intervals or 
concentrations up to 4 hours (Figure 2A-C; Figure 3A-C).  
 
 
Figure 3. The AMY1 receptor does not internalize robustly in response to hαCGRP. (A) Localization of 
[Cy53]-hαCGRP in AMY1 receptor transfected HEK293S cells, which was quantified at (B) varying time-
points and (C) peptide concentrations (CGRP receptor data replotted from Figure 2). [Cy53]-hαCGRP 
localization with (D) EEA-1 or (E) Myc-RAMP1 and HA-CTR in AMY1 receptor transfected HEK293S cells. 
(F) Cell surface expression of AMY1 receptor components by ELISA in HEK293S cells. In panels (A), (D) 
and (E), the images are representative of five (A, E) or four (D) independent experiments performed in 
duplicate. White arrows mark examples of spots. Scale bars = 20 µM. Other data are mean ± s.e.m., 
combined from five to ten (B), three (C) or five (F) independent experiments performed in duplicate or 
triplicate. In (B), * p <0.05 compared to vector transfected cells or # p <0.05 compared to the AMY1 receptor 
by repeated measures two-way ANOVA with a post hoc Bonferroni’s test. In (C), * p <0.05 compared to 
vector transfected cells by Student’s unpaired t-test at 100 nM [Cy53]-hαCGRP. In (F) myc and HA were 
compared to vehicle control treated cells (data not shown) at each time point by repeated measures two-
way ANOVA with a post-hoc Bonferroni’s test; there were no significant differences. In (A), (B), (D), (E) 10 
nM [Cy53]-hαCGRP was used. 
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At the CGRP receptor there was initially a rapid increase in the number of spots, 
consistent with agonist-induced receptor internalization, with the maximum level of 
internalization (mean number of spots per positively transfected cell) being detected after 
~30 minutes and then remaining stable for up to 4 hours (Figure 2B; vector control Figure 
S7). This was concentration-dependent with a mean pEC50 for internalization of [Cy53]-
hαCGRP being 8.80 ± 0.06 n=5 (Figure 2C). Quantification of immunofluorescence 
staining for the early endosomal marker EEA1 revealed co-localization with [Cy53]-
hαCGRP (Figure 2D, Figure S8), consistent with previous observations that the CGRP 
receptor is trafficked to early endosomes following agonist stimulation7, 10, 14. We 
confirmed these results with confocal microscopy (Figure S9). To verify that the [Cy53]-
hαCGRP label was found with the CGRP receptor, immunofluorescence staining against 
the HA tag on CLR was performed and quantified (Figure 2E, Figure S8). To support the 
immunofluorescence experiments, receptor cell surface expression was also measured 
using ELISA in HEK293S cells (Figure 2F) and a second cell line (Cos-7; Figure S10). 
In response to hαCGRP, there was a decrease in the cell surface expression of both 
CGRP receptor components over time, with a maximum decrease in cell surface 
expression observed after 60 to 90 minutes. 
 
When conducting matched experiments at the AMY1 receptor, there was a much smaller 
increase in the number of spots over time with significantly fewer spots observed at each 
time point compared to the CGRP receptor (Figure 3A, B). This was an apparent gradual 
increase over time, compared to the rapid agonist-driven internalization observed at the 
CGRP receptor (Figure 2B). Approximately 7-fold more [Cy53]-hαCGRP was required to 
drive AMY1 receptor internalization (pEC50 7.96 ± 0.13 n=5, * p < 0.05 vs. CGRP receptor 
by unpaired t test) (Figure 3C). Even 100 nM peptide produced less internalization at the 
AMY1 receptor, compared to the CGRP receptor; the mean (± s.e.m. n=5) number of 
spots for each receptor at 100 nM [Cy53]-hαCGRP was 5.64 ± 0.48 (CGRP receptor), 
compared to 3.15 ± 0.36 (AMY1 receptor); * p < 0.05 by unpaired t test. Hence, Higher 
concentrations of fluorescent ligand were not used due to greater non-specific binding at 
1 µM. EEA1 did not appear to co-localize robustly with [Cy53]-hαCGRP in AMY1 receptor 
transfected cells (Figure 3D, Figure S8). We confirmed these results with confocal 
microscopy (Figure S11). [Cy53]-hαCGRP did appear to co-localize with the CTR subunit 
of the AMY1 receptor but this was mostly on or close to the plasma membrane (Figure 
3E, Figure S8). In ELISA experiments at the AMY1 receptor, there was no time-
dependent decrease in either receptor component in either cell line in response to 
hαCGRP (Figure 3F, Figure S12A). 
 
As distinct ligands can differ in their ability to induce receptor internalization15, we sought 
to determine whether the lack of internalization observed at the AMY1 receptor was ligand 
dependent by measuring the internalization in response to amylin or the fluorescently 
labelled amylin analogue [Cy521]-pramlintide. In live cell imaging with [Cy521]-pramlintide, 
clear binding of the ligand to the plasma membrane of AMY1 transfected cells was 
observed, but very little fluorescence was observed within the cytoplasm (Movie 4). 
Quantification of the number of [Cy521-pramlintide] spots in fixed cells, revealed a gradual 
increase in the number of spots over time; this was very similar to that observed with 
[Cy53]-hαCGRP (Figure 4A, B; vector control Figure S13). Although [Cy521]-pramlintide 
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co-localized with the HA tag on CTR, like [Cy53]-hαCGRP at the AMY1 receptor, there 
was little co-localization of EEA1 with [Cy521]-pramlintide (Figure 4C, Figure S8). We 
confirmed these results with confocal microscopy (Figure S14). In ELISA; no decrease 
in the cell surface expression of either receptor component was observed in response to 
human amylin in HEK293S or Cos-7 cells, illustrating that these effects are consistent 
with three different ligands at the AMY1 receptor (Figure 4D, Figure S12B). We 
performed additional controls showing that CGRP and AMY1 receptor component 
expression was equivalent (Figure S15), and that the receptor tags were not affecting the 
outcome (Figure S16). We also developed a potent [Cy514]-human CT probe (pEC50 9.14 
± 0.21 n=5) which caused accumulation of bright spots in cells (Figure S17, S18), 
consistent with the ability of the CTR to internalize 16, 17. 
 
 
Figure 4. The AMY1 receptor does not internalize robustly in response to amylin agonists. (A) Localization 
of 10nM [Cy521]-pramlintide in AMY1 receptor transfected HEK293S cells, which was quantified at (B) 
varying time-points ([Cy53]-hαCGRP replotted from Figure 3). [Cy521]-pramlintide (10 nM) localization with 
(C) EEA-1 in AMY1 receptor transfected HEK293S cells. (D) Cell surface expression of AMY1 receptor 
components by ELISA in HEK293S cells. In panels (A) and (C), the images are representative of five (A) 
or three (C) independent experiments performed in duplicate. White arrows mark examples of spots. Scale 
bars = 20 µM. In (B) and (D), data are mean ± s.e.m., combined from five (B) or three (D) independent 
experiments performed in duplicate or triplicate. In (B), * p < 0.05 compared to vector transfected cells and 
# p < 0.05 compared to [Cy53]-hαCGRP at the AMY1 receptor by repeated measures two-way ANOVA with 
post hoc Bonferroni’s test. In (D) myc and HA were compared to vehicle control treated cells (data not 
shown) at each time point by repeated measures two-way ANOVA with a post-hoc Bonferroni’s test; there 
were no significant differences. hAmy; human amylin. 
 
The duration of agonist stimulation is reported to affect the trafficking profile of the CGRP 
receptor, with chronic stimulation resulting in trafficking to lysosomes and degradation8. 
To determine whether this occurs with the AMY1 receptor, transfected cells were 
stimulated with 100 nM CGRP or control media for 30 minutes or four hours and receptor 
degradation was monitored by western blotting (Figure 5). Four hours of stimulation of 
the CGRP receptor was sufficient to induce significant degradation of CLR (with RAMP1). 
In comparison no degradation of CTR (with RAMP1) was observed. These data strongly 
support our findings of the distinct consequences for each receptor in response to ligand 
stimulation.  
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The consequences on signaling are less clear. There is conflicting evidence on whether 
the CGRP receptor is desensitized in response to agonist stimulation 18, 19. CGRP and 
AMY1 receptors signal through many of the same signaling pathways20. However it is not 
yet known whether CGRP receptor signaling from endosomes results in activation of 
distinct signaling pathways, compared to the AMY1 receptor. Further investigation in 
native tissues will be required to confirm whether our observed differences in receptor 
trafficking are a universal difference for these receptors, or are cell background-
dependent. It would also be useful to better understand the implications on signaling. 
 
 
Figure 5. The CGRP receptor undergoes agonist-induced degradation, unlike the AMY1 receptor. (A) 
Western blot of CGRP receptor and AMY1 transfected HEK293S cell lysates treated with 100 nM hαCGRP 
or vehicle for 30 minutes or four hours, probed with anti-HA, anti-GAPDH and anti-myc antibodies. (B) 
Quantification of HA-CLR or HA-CTR band intensities from western blots. In (A), western blots are 
representative of four independent experiments. In (B) data are normalized to the untreated 30 minute 
band. * p < 0.05 by Student’s paired t-test. In (C), the band between the markers at 29 and 37 is consistent 
with the RAMP1 dimer. 
 
A potential mechanistic explanation for our result is that while the overall amino acid 
sequences of the CLR and CTR are similar (~70% sequence similarity), there are 
significant differences within their C-terminal tails. The C-terminal tail is critical for the 
internalization of the CGRP receptor, with deletion resulting in reduced internalization21. 
Many Ser/Thr residues, which are potential phosphorylation sites and likely to drive β-
arrestin interactions, are present within the CLR C-terminal tail and intracellular loops. In 
contrast, CTR has considerably fewer Ser/Thr residues and may therefore be subject to 
less phosphorylation, and be less able to recruit β-arrestins than CLR8. A similar paradigm 
has been reported for the β1 and β2 adrenergic receptors, where the β1 adrenergic 
receptor displays little agonist-induced receptor phosphorylation or internalization 
compared to the β2 adrenergic receptor 22, 23. We speculate that the larger apparent 
molecular weight of CLR after 30 minutes of CGRP treatment is due to post-translational 
modification of the receptor. In contrast this is not seen with CTR (Figure 5). 
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Despite the low number of Ser/Thr residues in the intracellular regions of CTR, there are 
several previous reports of CTR internalization8, although the mechanisms by which this 
occurs are unclear as CTR is not reported to interact with arrestins when simulated with 
peptide agonists17. It has also been reported that CTR undergoes constitutive agonist-
independent recycling 16, 17. In our hands, CTR demonstrated some internalization. It is 
possible that constitutive recycling of CTR accounts for the discrepancy between the 
limited uptake of labelled peptides and the lack of receptor internalization observed by 
ELISA in AMY1 receptor transfected cells, although this requires further investigation. 
Interestingly, it appears that RAMP1 association with CTR reduced its ability to 
internalize, based on greater internalization of CTR alone compared CTR co-transfected 
with RAMP1 (Figure S19). Although the mechanism for this is not known, and requires 
further study, this suggests that RAMP1 is able to affect GPCR regulation. RAMP3 
contains a PDZ motif in its C-terminal tail which alters the recycling properties of the AM2 
receptor, through its interactions with PDZ domain-containing proteins NHERF and NSF 
24, 25. An effect of RAMPs on internalization has not previously been reported and 
therefore this is a potentially novel function for RAMPs in altering GPCR behavior. We 
cannot rule out the possibility that AMY1 is undergoing fast recycling or being internalized 
to a distinct subcellular compartment that is closely associated with the plasma 
membrane and this should be investigated in future studies. It will also be important to 
carefully compare where the ligands and receptors are found in different intracellular 
pools, including endosomes. 
 
The precise physiological role of CGRP and AMY1 receptors in response to CGRP is 
unclear, but as both receptors are expressed within the trigeminovascular system11, both 
receptors may contribute to CGRP signaling in migraine. Both receptors signal through 
the same pathways20, therefore it has been difficult to determine the role of each receptor. 
Here we demonstrate a clear functional difference between the CGRP and AMY1 
receptors. As the AMY1 receptor appears to be retained at the cell surface in response to 
CGRP stimulation, under conditions of elevated CGRP such as migraine, it may represent 
a novel drug target. Furthermore the potent fluorescent labeled peptides developed in this 
study have other potential applications, including single molecule, biodistribution and 





Plasmids   
The following DNA constructs were used, human CLR with an N-terminal HA tag in 
pcDNA3.1- , Human CTR (a isoform) with N-terminal HA tag in pcDNA3.1, or untagged 
CTR. RAMP1 with an N-terminal myc tag, or untagged RAMP1. These constructs have 
been previously described 26-30. CLR or CTR were transfected in a 1:1 ratio with RAMPs. 
Where CTR was not transfected with RAMP, pcDNA3.1 was used in its place. 
 
Peptide chemistry  
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Unlabelled hαCGRP, hAmylin or hCT were synthesized in-house as previously described 
27, 31, 32. Human adrenomedullin was from Bachem (Bubendorf, Switzerland). Full details 
of the synthesis of [Cy53]-hαCGRP, [Cy521]-hαCGRP, [Cy514]-hCT and [Cy521]-
pramlintide are described in Supporting Information. In all cases, a lysine was 
incorporated into the sequence in place of the native amino acid to facilitate labelling. 
 
Mammalian Cell Culture and transfection 
HEK293S and Cos-7 cells were cultured as previously described33. Briefly, cells were 
cultured in DMEM high glucose (Cat #11965092) (Thermo-fisher, Waltham, MA, USA), 
supplemented with 8% fetal bovine serum (Life Technologies, Carlsbad, CA, USA), in a 
37 °C humidified incubator with 5% CO2. 
 
For live cell imaging and immunofluorescence experiments, HEK293S cells were plated 
into 96-well cell-carrier or cell-carrier ultra plates (Perkin-Elmer, Waltham, MA, USA) pre-
coated with poly-D-lysine (#354210, Corning, Corning, NY, USA) at a density of 10,000 
cells per well. Cells were transfected after 36 hours, with 0.25 μg DNA with 
polyethylenimine (PEI) as previously described 26. After 24-36 hours cells were used for 
live cell imaging or immunofluorescence experiments. 
 
For cAMP assays and ELISAs; Cos-7 cells were plated in 96-well SpectraPlates (Perkin-
Elmer) at a density of 20,000 cells per well. HEK293S cells were plated in 96-well CellBind 
plates (Corning) at a density of 25,000 cells per well. After 24 hours, cells were transfected 
with 0.25 μg of DNA using PEI and cultured for a further 48 hours before assays. 
 
For the degradation assays, HEK293S cells were plated into 6-well plates (Greiner, 
Kremsmuenster, Austria) at a density of ~ 500,000 cells per well. After 24 hours, cells 
were transfected with 5 μg of DNA using PEI and cells were cultured for a further 48 hours 
before being assayed. 
 
Live cell imaging 
Cells were serum starved in Hank’s Balanced Salt Solution (#14025-092, Thermo-Fisher) 
(HBSS) with 0.1% BSA for 30 minutes at 37 °C and then placed in the live cell imaging 
chamber of an Operetta high-content imaging system (Perkin-Elmer) pre-incubated to 37 
°C + 5% CO2. Cells were imaged once before 100 nM of fluorescently labelled peptide 
was added. Cells were subsequently imaged every 30 seconds for 1 hour.  
 
Immunofluorescence 
Cells were washed and serum starved for 30 minutes at 37 °C in DMEM + 0.1% BSA. 
Cells were incubated with 10 nM of fluorescent peptide, for varying amounts of time at 37 
°C. Following incubation cells were washed twice with ice-cold PBS and fixed for 10-20 
minutes with 4% PFA. Following fixation, cells were either permeabilized for staining of 
intracellular markers and receptors, or left non-permeabilized for the quantification 
fluorescent peptide staining. 
 
For non-permeabilized cells, cells were fixed with 4% PFA for 20 minutes at room 
temperature and blocked with PBS containing 10% goat serum for 1 hour at room 
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temperature. Cells were then incubated with primary mouse anti-myc antibody at a 
dilution of 1:250 (#MABE282, Merck, Darmstadt, Germany) in PBS containing 1% goat 
serum for 30 minutes at 37 °C. Cells were then incubated with a secondary anti-mouse 
Alexa-555 conjugate antibody at a dilution of 1:200 (Life-Technologies #A32727) in PBS 
containing 1% goat serum for 30 minutes at 37 °C. Cells were stained with HCS Cell Mask 
Blue (Life-technologies #H32720) in PBS. 
 
For experiments visualizing fluorescent peptides with EEA1, cells were first permeabilized 
by incubating with TBS-Tween20 in 10% goat serum (Thermo-Fisher) for 30-60 minutes 
at room temperature. Cells were then incubated with rabbit anti-HA antibody at a dilution 
of 1:1000 (#ab20084, abcam, Cambridge, UK) or anti-EEA1 antibody at 1:500 (#610457, 
BD, Franklin Lakes, NJ, USA)), in TBS-T containing 1% goat serum at room temperature 
for 1 hour, followed by staining HCS Cell Mask Blue (#H32720) for 30 minutes at room 
temperature. For co-localization experiments with anti-HA and anti-myc, antibody 
incubations were performed at 37 °C for 30 minutes and anti-rabbit Alexa-555 (Life-
Technologies #A32732) and anti-mouse Alexa-488 (Life-Technologies #A32723) were 
used at 1:200 dilutions. 
 
Cells were imaged using an Operetta high-content imaging system in wide-field 
fluorescence mode using a 40x long WD objective (NA 0.6) (Perkin-Elmer). Images were 
stored as 16-bit TIFF files. Images were minimally processed with ImageJ to adjust the 
color and brightness of images for visualization. Changes were applied consistently 
across images for comparison.  
 
cAMP assay 
LANCE cAMP assay was performed as previously described 27. All cAMP assays were 
performed in the presence of 1 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich, 
St. Louis, MO, USA) and contained 0.1% DMSO. Briefly, Cos-7 cells were serum starved 
in cAMP assay media (DMEM + 0.1% BSA + 1 mM IBMX) for 30 minutes at 37 °C. 
Peptides were serial diluted in cAMP assay media and cells were incubated with the 
peptide, media alone or forskolin control for 15 minutes at 37 °C. Media was then 
aspirated and the reaction stopped by incubating with ice-cold absolute ethanol. Ethanol 
was evaporated and cAMP measured using the LANCE cAMP detection kit (PerkinElmer) 
as previously described20. 
 
Cell surface ELISA  
ELISA was performed as described previously to determine receptor cell surface 
expression 34, with the following modification; the secondary antibody step was performed 
using goat anti-mouse HRP conjugate (# A16066, Life Technologies) at a 1:500 dilution 
and incubated for 30 minutes at 37 °C. 
 
Degradation Assay 
HEK293S cells were serum starved with DMEM + 0.1% BSA + 20 μg/mL cyclohexamide 
(Sigma #01810) for 1 hour at 37 °C. Cells were stimulated with 100 nM hαCGRP or assay 
media for either 30 minutes or 4 hours at 37 °C. Following incubation, cells were washed 
with PBS then detached with a solution of PBS/0.5 mM EDTA. Cells were pelleted by 
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centrifugation at 500 x g. The cell pellet was then resuspended in 1% dodecyl maltoside 
(DDM) (Anatrace, Maumee, OH, USA), 0.1% Cholesteryl hemisuccinate (Anatrace) 
supplemented with complete protease inhibitor tablets (Roche, Basel, Switzerland) and 
incubated for 2 hours at 4 °C. The lysate was clarified by centrifugation at 30,000 x g for 
20 minutes. Total protein was determined using a BCA protein assay kit (Pierce, 
Waltham, MA, USA).  
 
SDS-PAGE and Western Blotting 
20-30 μg of whole cell lysates from the degradation assay was loaded on to 4-12% 
SurePage Bis-Tris gels (GenScript, Piscataway, NJ, USA). An equal amount was loaded 
in each lane in each individual experiment. There was slight variation between 
experiments due to variation in the amount of sample obtained. Proteins were transferred 
to nitrocellulose membranes (Biorad, Hercules, CA, USA) at 100 V for 45 minutes. Blots 
were blocked with 5% Milk in TBS-T. Blots were then incubated with mouse anti-HA 
1:1000 (# 901503, Biolegend, San Diego, CA, USA), mouse anti-GAPDH 1:4000 
(#TA802519, Rockville, MD, USA) and mouse anti-myc 1:500 (Merck #MABE282) 
antibodies in 5% TBS-T for 1 hour at 37 °C. Blots were washed then incubated with goat 
anti-mouse-HRP conjugate at a dilution of 1:3000 (#A16066, Life Technologies) for 1 hour 
at room temperature. Blots were developed by incubation with SuperSignal West Pico 
Plus (Pierce #34577) for 5 minutes. Imaging of blots was performed using an Amersham 
A600 imager (GE Healthcare, Chicago, IL, USA). Image acquisition was performed using 
the automated exposure function with the high dynamic range setting.  
 
Image Analysis 
All analysis was performed on unprocessed images. Spot counting was performed using 
Columbus (Perkin-Elmer). Full details of this analysis are described in supporting 
information (Figure S5, S6). Co-localization analysis was performed in the FIJI 
distribution of ImageJ using the EzColocalization plugin35. A cell mask was first applied 
to cells positive for Cy5 staining, co-localization of Cy5 fluorescence with either HA or 
EEA1 staining was then determined by measuring Pearson’s correlation coefficient 
(PCC). A single PCC value were determined for each group from ~20 cells in each 
individual experiment. The data were combined to generate a mean value from three to 
four independent experiments. 
 
Data and Statistical Analysis 
All data are the mean ± the standard error of the mean (s.e.m.), combined from three to 
ten independent experiments. All data were analyzed using Prism GraphPad 8.0.2 
(GraphPad Software, La Jolla, CA). 
 
Cell signaling – For each individual experiment concentration-response curves were fitted 
using three or four-parameter nonlinear regression as determined by F-test. Individual 
pEC50 values were combined to generate mean data. pEC50 values were analyzed using 
one-way ANOVA with post hoc Dunnett’s test or unpaired Student’s t-test.  Data were 
normalized to the maximum response of the control unmodified peptide in each individual 
experiment and combined for presentation. Transduction ratios (log(τ/KA)) were quantified 
using the operational model of agonism as previously described36. The maximal response 
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window of the system was defined as the largest normalized Emax recorded across the 
entire dataset. All curves were constrained by setting n to 1, and the Emax as the maximal 
response window of the system. All curves were then fit as “partial agonists” relative to 
this Emax. Individual log(τ/KA) values were combined to generate mean data. Log(τ/KA) 
values were analyzed using one-way ANOVA with post hoc Dunnett’s test or unpaired 
Student’s t-test. 
 
Spot counting - For time course data, five to ten independent experiments were combined 
and a repeated measures two-way ANOVA with a post hoc Bonferroni's test was 
performed comparing spots of fluorescent-peptide at each receptor to the vector control 
at each time-point. For concentration response data, data were analyzed for pEC50 values 
as described for Cell signaling. However, no pEC50 could be generated from vector-
transfected cells. Therefore, a Student’s t-test was performed comparing the response at 
the maximum concentration of fluorescently labelled peptide used. 
 
Cell surface ELISA - Three to five independent experiments were conducted. In each 
independent experiment, values were normalized to vector transfected cells (0%) and the 
receptor component expression in unstimulated cells at 0 minutes (100%), then 
combined. Statistical analysis was via repeated measures two-way ANOVA with a post 
hoc Bonferroni's test  on the combined normalized data comparing receptor component 
expression in stimulated cells with vehicle-treated cells at each time-point (data not 
shown). 
 
Western blot images were analyzed in Image Studio Lite v 5.2 (LI-COR biosciences, 
Lincoln, NE, USA) using the unprocessed TIFF files. The intensity of HA and GAPDH 
bands were measured by drawing a box around each band. HA band intensity data were 
normalized to the intensity of the GAPDH loading control, then normalized to the 
untreated 30 minute HA band. Statistical analysis was performed using Student’s 




Supporting Information.  
 
Additional biology methodology (spot counting – time courses, sport counting – 
concentration-response curves, confocal microscopy, cell signaling assays – ERK1/2, 
CREB phosphorylation), results tables and figures (cAMP production concentration-
response curves and tabulated data with heat map, pERK1/2 and pCREB 
concentration-response curves and tabulated data, live cell imaging images, spot 
analysis workflow, cell mask blue and green overlap, vector control data, colocalisation 
data, confocal microscopy images, Cos-7 cell ELISAs, comparison of cell surface 
expression, untagged receptor ELISAs, labeled calcitonin data), Chemistry general 
procedure and general methods, synthesis of fluorescent peptides. 
 
Supporting Movies  
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Movie 1. Live cell imaging of [Cy53]-hαCGRP in CGRP receptor transfected HEK293S 
cells. Cells were incubated with 100 nM [Cy53]-hαCGRP at 37 °C and images were 
acquired at 30 second intervals for 1 hour. Images were captured using the 40x objective 
on an Operetta high content imager. Video is representative of three independent 
experiments.  
 
Movie 2. Live cell imaging of [Cy53]-hαCGRP in AMY1 receptor transfected HEK293S 
cells. Cells were incubated with 100 nM [Cy53]-hαCGRP at 37 °C and images were 
acquired at 30 second intervals for 1 hour. Images were captured using the 40x objective 
on an Operetta high content imager. Video is representative of three independent 
experiments.  
 
Movie 3. Live cell imaging of [Cy53]-hαCGRP in pcDNA transfected HEK293S cells. Cells 
were incubated with 100 nM [Cy53]-hαCGRP at 37 °C and images were acquired at 30 
second intervals for 1 hour. Images were captured using the 40x objective on an Operetta 
high content imager. Video is representative of three independent experiments.  
 
Movie 4. Live cell imaging of [Cy521]-pramlintide in AMY1 transfected HEK293S cells. 
Cells were incubated with 100 nM [Cy521]-pramlintide at 37 °C and images were acquired 
at 30 second intervals for 1 hour. Images were captured using the 40x objective on an 
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This graphic shows how the CGRP receptor internalizes in response to CGRP but the 
AMY1 receptor does not show robust internalization in response to CGRP, amylin or 
pramlintide. 
 
 
